Dave Asprey's Substack

Dave Asprey's Substack

Ozempic is making you thinner. It might also be making you weaker, slower, and older.

The muscle loss nobody is talking about, and what to do about it.

May 04, 2026
∙ Paid

A few years ago I took one low dose injection of Ozempic so I could record an episode with Dr. Robert Kushner, one of the researchers behind the original semaglutide trials. I felt nauseous the entire time and didn’t want to eat. One injection, and I was done with it.

After that I started paying close attention to what these drugs actually do to your body. Weight loss numbers get all the headlines. What’s happening to your muscle gets almost none.

Millions of people are taking semaglutide and tirzepatide right now, and retatrutide is one to watch. It’s a triple agonist hitting GLP-1, GIP, and glucagon receptors simultaneously, and early Phase 2 data showed weight loss approaching 24%.

If you’re on one of these drugs you’re probably losing weight. What you may not know is how much of that weight is muscle.

Losing fat is good. Losing muscle in the process is one of the worst things you can do for your long-term health.

In the paid section you’ll learn:

  • Why muscle loss on GLP-1 drugs is a bigger problem than the industry admits

  • What happens to your metabolism when lean mass drops fast

  • The exact protocol I use to protect muscle while losing fat

  • Why people who stop these drugs gain all the weight back

[Subscribe for the full article]

User's avatar

Continue reading this post for free, courtesy of Dave Asprey.

Or purchase a paid subscription.
© 2026 Dave Asprey · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture